HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer Trims Consumer Portfolio Selling Solarcaine, Other US, Canada Skin Care Brands To WellSpring

Executive Summary

WellSpring, owned by private equity firm Avista Capital Partners, purchasing Solarcaine, diaper rash and skin protectant A+D and Canadian brands Cortate and Complex 15. Bayer’s long-term commitment to consumer health one of key issues facing its next CEO, Bill Anderson.

You may also be interested in...



Perrigo’s Next CEO Has Long OTC Brands History

Patrick Lockwood-Taylor starts as president/CEO on 30 June, succeeding Murray Kessler as Perrigo awaits FDA decision on subsidiary HRA’s proposal for first US OTC sales of daily oral contraceptive. He’s moving from president of Bayer AG’s US business and regional president, consumer health North America.

Top Five Takeaways From Bayer Consumer Health's 2022 Results

Beating global market growth, continuing macroeconomic headwinds and spin-off perspectives were among the key talking points as Bayer Consumer Health reported its 2022 sales and earnings.

Bayer’s Incoming CEO Faces Consumer Health Decision

Activist investors are pushing for a break-up of Bayer's conglomerate structure and the sale of its Consumer Health division. It will be up to incoming CEO Bill Anderson to make the call.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153540

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel